Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study

Clinical Therapeutics

Volumn 22, Issue 12, 2000, Pages 1395-1409

  Einhorn, Daniel ^a   Rendell, Marc ^b,c   Rosenzweig, James ^d   Egan, John W ^e,f   Mathisen, Annette L ^e   Schneider, Roberta L ^e  

^a SHARP HEALTHCARE   (United States)

^b Creighton Diabetes Center   (United States)

^c Rose Salter Medical Research Foundation   (United States)

^d JOSLIN DIABETES CENTER   (United States)

^e Takeda America Research and Development Center Inc   (United States)

^f TAKEDA PHARMACEUTICALS   (United States)

Author keywords

Glycemic control; Lipids; Metformin; Pioglitazone

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PIOGLITAZONE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034531195     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)83039-8     Document Type: Article

References (28)

1. The pathophysiology of type II (noninsulin-dependent) diabetes mellitus: Implications for treatment
2. Oral hypoglycemic agents
3. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
4. Metabolic effects of metformin in noninsulin-dependent diabetes mellitus
5. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in over-weight type II diabetic patients
6. Pharmacologic therapy for type 2 diabetes mellitus
7. Pioglitazone hydrochloride
8. Mechanisms and clinical effects of thiazolidinediones
9. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys
10. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats
11. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals
12. Clinical practice recommendations 2000
13. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
14. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man
15. The homeostasis model in the San Antonio Heart Study
16. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
19. Glucose clamp technique: A method for quantifying insulin secretion and resistance
20. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
21. Plasma lipids and diabetes mellitus in an adult community
22. Management of dyslipidemia in adults with diabetes
23. Lipids, glucose intolerance and vascular disease: The Framingham Study
24. Rosiglitazone
25. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials
26. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
27. Rosiglitazone therapy is not associated with hepatotoxicity
28. Rosiglitazone liver safety update